The collaboration will involve the permanent presence of a Farminerva S.r.l. section on the science park, and will join two other biotechnology companies present there (LayLine Genomics and BioLab). Effort will be dedicated to accelerating domestic and international partnerships to in-license or co-develop new intellectual property with the aim to move the development as far as possible up the biomedical product value chain, prior to out-licensing for significant value creations.
Fondazione Parco Biomedico San Raffaele (PSB)
Located approximately 15 km south of Rome in a natural reserve, the science park was created by the Banca di Roma, the Chamber of Commerce of Rome, and the Fondazione San Raffaele Monte Tabor in response to the recognised need to have a biomedical research centre in the Lazio region. Opened in 2002, the park is now home to 3 companies and 9 research groups from Universities and centres working in: Stem cells, Oncology, leukaemia and Immunology; Molecular cardiology; Skeletal regeneration; Cell therapy and tissue engineering; Muscular dystrophies; Biomedical quality control; Neurological Disorders and Diabetes. The infrastructure permits the development of concept to preclinical development based on the state-of-the-art facilities including a animal facility encompassing conventional and SPF small animals and a large animal surgery unit.
Farminerva is a private company, founded in 2006, focused on research activities to reach new advanced solutions in biomedical sector. These objectives are developed by a strong cooperation with academic and institutional centres, as the Fondazione Parco Biomedico San Raffaele and CRISC of the Rome University, where Farminerva sponsors the execution of all preclinical and clinical studies requested by local regulatory authorities to obtain marketing license.
This collaboration defines a platform which promotes and coordinates research projects from preclinical to clinical phases to improve specific knowledge in two particular field: the first one concerns new products useful in early diagnosis of orthopaedic, cardiovascular, bone tissue inflammatory and/or infective based diseases, diabetic and oncological diseases. Further effort will be targeted on developing drugs for treatment of infective, diabetic and oncological diseases.
The other one aims to discovery new therapeutic indication of generic drugs to treat neurological, psychiatric and abuse disorders (second/other medical use), through the participation of CNR IASI researchers which perform advanced statistical analysis on large database (1/3 million of subjects) to identify co-morbidity data of relevant clinic interest.
About 50 free lance professionals work in Farminerva projects to ensure high quality level in management and monitoring activities and significantly shorter time to achieve the marketing phase.
Jonathan Dando | alfa
Researchers identify potentially druggable mutant p53 proteins that promote cancer growth
09.12.2016 | Cold Spring Harbor Laboratory
Plant-based substance boosts eyelash growth
09.12.2016 | Fraunhofer-Institut für Angewandte Polymerforschung IAP
Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.
Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
09.12.2016 | Life Sciences
09.12.2016 | Ecology, The Environment and Conservation
09.12.2016 | Health and Medicine